Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.51 |
| ▸ | SMYD3 | Q9H7B4 | 2/20 | 0.49 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.47 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.47 |
| ▸ | GAA | P10253 | 2/20 | 0.47 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.47 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.47 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.47 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.47 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.47 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.47 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.47 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.47 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.47 |
| ▸ | KDM1A | O60341 | 2/20 | 0.46 |
| ▸ | MAOA | P21397 | 2/20 | 0.46 |
| ▸ | MAOB | P27338 | 2/20 | 0.46 |
| ▸ | KDM1B | Q8NB78 | 2/20 | 0.46 |
| ▸ | RCOR1 | Q9UKL0 | 2/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5564619 | 0.98 | USP30 (0.51) | USP30SMYD3HDAC8HDAC6GAA | |
| SCHEMBL5567680 | 0.85 | SMYD3 (0.54) | USP30SMYD3HDAC8HDAC6GAA | |
| SCHEMBL4691942 | 0.84 | F10 (0.58) | NPC1RAB9ATP53MAPK1SMN1; SMN2 | |
| SCHEMBL5564623 | 0.82 | SMYD3 (0.54) | USP30SMYD3HDAC8HDAC6GAA | |
| SCHEMBL4690484 | 0.82 | F10 (0.61) | NPC1RAB9ATP53MAPK1SMN1; SMN2 | |
| SCHEMBL4742421 | 0.81 | F10 (0.59) | SMYD3KDM1AMAOAMAOBRCOR1 | |
| SCHEMBL15866466 | 0.79 | NPC1 (0.68) | USP30SMYD3GAAKDM4ENPC1 | |
| SCHEMBL4694872 | 0.79 | RAB9A (0.67) | NPC1RAB9AMAPTALDH1A1TP53 | |
| SCHEMBL5432613 | 0.78 | F10 (0.57) | SMYD3KDM1AMAOAMAOBRCOR1 | |
| SCHEMBL5435543 | 0.78 | F10 (0.59) | SMYD3NPC1RAB9AALDH1A1TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1670739-A4 | CYCLIC DIAMINES AND DERIVATIVES AS FACTOR XA INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2007-08-08 | — | — | EP | claimed |
| EP-1670739-A2 | CYCLIC DIAMINES AND DERIVATIVES AS FACTOR XA INHIBITORS | Bristol-Myers Squibb Company (US) | 2006-06-21 | — | — | EP | claimed |
| US-20050085511-A1 | Cyclic diamines and derivatives as factor Xa inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2005-04-21 | — | — | US | claimed |
| WO-2005032490-A2 | CYCLIC DIAMINES AND DERIVATIVES AS FACTOR XA INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2005-04-14 | — | — | WO | claimed |
| EP-1670739-A4 | CYCLIC DIAMINES AND DERIVATIVES AS FACTOR XA INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2007-08-08 | — | — | EP | disclosed |
| US-7115646-B2 | Cyclic diamines and derivatives as factor Xa inhibitors | BRISTOL MYERS SQUIBB, CO. (US) | 2006-10-03 | — | — | US | disclosed |
| EP-1670739-A2 | CYCLIC DIAMINES AND DERIVATIVES AS FACTOR XA INHIBITORS | Bristol-Myers Squibb Company (US) | 2006-06-21 | — | — | EP | disclosed |
| US-20050085511-A1 | Cyclic diamines and derivatives as factor Xa inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2005-04-21 | — | — | US | disclosed |
| WO-2005032490-A2 | CYCLIC DIAMINES AND DERIVATIVES AS FACTOR XA INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2005-04-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050085511-A1 | Cyclic diamines and derivatives as factor Xa inhibitors | TFPI, SERPINC1, F12 | USP30 4232/4885SMYD3 2684/4885HDAC8 836/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.